

Title (en)

HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

Title (de)

HYDROPYRIDO[1,2-ALPHA]PYRAZINVERBINDUNGEN ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN

Title (fr)

COMPOSÉS D'HYDROPYRIDO[1,2-ALPHA]PYRAZINE POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE

Publication

EP 4069693 A1 20221012 (EN)

Application

EP 20819661 A 20201201

Priority

- CN 2019122716 W 20191203
- EP 2020083996 W 20201201

Abstract (en)

[origin: WO2021110614A1] The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds act as antagonists of the toll-like receptors TLR7, TLR8 and/or TLR9 and are thus useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

IPC 8 full level

C07D 471/04 (2006.01); **A61K 31/497** (2006.01); **A61P 37/00** (2006.01); **A61P 37/02** (2006.01); **C07D 519/00** (2006.01)

CPC (source: EP US)

A61P 37/00 (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **C07D 471/04** (2013.01 - EP US); **C07D 519/00** (2013.01 - EP US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2021110614 A1 20210610; CN 114761406 A 20220715; CN 114761406 B 20240419; EP 4069693 A1 20221012; EP 4069693 B1 20240320; EP 4069693 C0 20240320; JP 2023505159 A 20230208; US 2023022297 A1 20230126

DOCDB simple family (application)

EP 2020083996 W 20201201; CN 202080083352 A 20201201; EP 20819661 A 20201201; JP 2022533088 A 20201201; US 202017780161 A 20201201